Timothy G. Murray
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Timothy G. Murray has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Amy C. Schefler
Retina Consultants of Houston
12 shared publications William Feuer
From the Bascom Palmer Eye Institute and
9 shared publications- Colleen M. Cebulla
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Columbus Ohio USA
8 shared publications Hinda Boutrid
From *Dartmouth Medical School, Hanover, New Hampshire; †Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida; and ‡Rosalind Franklin University of Medicine and Science, North Chicago, Illinois
7 shared publicationsArmando Alegret
From the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida; and
6 shared publicationsMaria-Elena Jockovich
From the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miami, Florida; and
6 shared publications
Latest Publications
- 1 December 2013
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 73 (2) , 349-361
Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-d-glucose
Background As tumors evolve, they upregulate glucose metabolism while also encountering intermittent periods of glucose deprivation. Here, we investigate mechanisms by which pancreatic cancer cells respond to therapeutic (2-deoxy-d-glucose, 2-DG) and physiologic (glucose starvation, GS) forms of glucose restriction. Methods From a tumor cell line (1420) that is unusually sensitive to 2-DG under normoxia, low (14DG2)- and high (14DG5)-dose resistant cell lines were selected and used to probe the metabolic pathways involved with their response to different forms of glucose deprivation. Results Muted induction of the unfolded protein response was found to correlate with resistance to 2-DG. Additionally, 14DG2 displayed reduced 2-DG uptake, while 14DG5 was cross-resistant to tunicamycin, suggesting it has enhanced ability to manage glycosylation defects. Conversely, 2-DG-resistant cell lines were more sensitive than their parental cell line to GS, which coincided with lowered levels of glycogen phosphorylase (PYGB) and reduced breakdown of glycogen to glucose in the 2-DG-resistant cell lines. Moreover, by inhibiting PYGB in the parental cell line, sensitivity to GS was increased. Conclusions Overall, the data demonstrate that the manner in which glucose is restricted in tumor cells, i.e., therapeutic or physiologic, leads to differential biological responses involving distinct glucose metabolic pathways. Moreover, in evolving tumors where glucose restriction occurs, the identification of PYGB as a metabolic target may have clinical application.
- 1 December 2013
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 73 (2) , 349-361
Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-d-glucose
Background As tumors evolve, they upregulate glucose metabolism while also encountering intermittent periods of glucose deprivation. Here, we investigate mechanisms by which pancreatic cancer cells respond to therapeutic (2-deoxy-d-glucose, 2-DG) and physiologic (glucose starvation, GS) forms of glucose restriction. Methods From a tumor cell line (1420) that is unusually sensitive to 2-DG under normoxia, low (14DG2)- and high (14DG5)-dose resistant cell lines were selected and used to probe the metabolic pathways involved with their response to different forms of glucose deprivation. Results Muted induction of the unfolded protein response was found to correlate with resistance to 2-DG. Additionally, 14DG2 displayed reduced 2-DG uptake, while 14DG5 was cross-resistant to tunicamycin, suggesting it has enhanced ability to manage glycosylation defects. Conversely, 2-DG-resistant cell lines were more sensitive than their parental cell line to GS, which coincided with lowered levels of glycogen phosphorylase (PYGB) and reduced breakdown of glycogen to glucose in the 2-DG-resistant cell lines. Moreover, by inhibiting PYGB in the parental cell line, sensitivity to GS was increased. Conclusions Overall, the data demonstrate that the manner in which glucose is restricted in tumor cells, i.e., therapeutic or physiologic, leads to differential biological responses involving distinct glucose metabolic pathways. Moreover, in evolving tumors where glucose restriction occurs, the identification of PYGB as a metabolic target may have clinical application.
- Open Access
- 1 February 2013
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 7, 427-435
Microincisional vitrectomy for retinal detachment in I-125 brachytherapy-treated patients with posterior uveal malignant melanoma
Purpose: To analyze functional and anatomical outcomes following 23/25+ gauge microincisional pars plana vitrectomy surgery (MIVS) in patients with radiation-related retinal detachment after successful 125-iodine (I-125) brachytherapy treatment for malignant uveal melanoma. Patients and methods: Retrospective case series of 102 consecutive eyes of 102 patients with history of uveal melanoma treated with I-125 brachytherapy that underwent MIVS at the Bascom Palmer Eye Institute. All cases were evaluated for surgical complications and local tumor control. Extended follow-up included Snellen’s best-corrected visual acuity, intraocular pressure evaluation, quantitative echography, indirect ophthalmoscopy, and fundus imaging with optical coherence tomography/wide-field photography. Results: All patients had radiation-related complications, including retinal detachment (102 eyes), vasculopathy (91 eyes), optic neuropathy (32 eyes), and/or vitreous hemorrhage (8 eyes). Sixty-seven patients had vitreoretinal traction. Average follow-up after MIVS was 19.5 months, and from plaque removal was 57.7 months. Interval from plaque to MIVS was 38.1 months. Initial visual acuity was 20/258, which improved to 20/101 at 1 month, 20/110 at 3 months, 20/116 at 6 months, and 20/113 at 12 months (P < 0.05). No eyes required enucleation. Melanoma-related mortality was 0.9% (1/102). There was no intra- or extraocular tumor dissemination, and no tumor recurrence. Conclusion: MIVS was effective in improving visual function and anatomy in patients with radiation-related retinal detachment. Tumors decreased in size and there was no evidence of recurrence or tumor dissemination. This combined procedure addresses the modifiable causes of visual loss in patients with previously treated malignant uveal melanoma and has the potential to enhance their visual function.
- 1 February 2013
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 7, 427-435
Open AccessMicroincisional vitrectomy for retinal detachment in I-125 brachytherapy-treated patients with posterior uveal malignant melanoma
Purpose: To analyze functional and anatomical outcomes following 23/25+ gauge microincisional pars plana vitrectomy surgery (MIVS) in patients with radiation-related retinal detachment after successful 125-iodine (I-125) brachytherapy treatment for malignant uveal melanoma. Patients and methods: Retrospective case series of 102 consecutive eyes of 102 patients with history of uveal melanoma treated with I-125 brachytherapy that underwent MIVS at the Bascom Palmer Eye Institute. All cases were evaluated for surgical complications and local tumor control. Extended follow-up included Snellen’s best-corrected visual acuity, intraocular pressure evaluation, quantitative echography, indirect ophthalmoscopy, and fundus imaging with optical coherence tomography/wide-field photography. Results: All patients had radiation-related complications, including retinal detachment (102 eyes), vasculopathy (91 eyes), optic neuropathy (32 eyes), and/or vitreous hemorrhage (8 eyes). Sixty-seven patients had vitreoretinal traction. Average follow-up after MIVS was 19.5 months, and from plaque removal was 57.7 months. Interval from plaque to MIVS was 38.1 months. Initial visual acuity was 20/258, which improved to 20/101 at 1 month, 20/110 at 3 months, 20/116 at 6 months, and 20/113 at 12 months (P < 0.05). No eyes required enucleation. Melanoma-related mortality was 0.9% (1/102). There was no intra- or extraocular tumor dissemination, and no tumor recurrence. Conclusion: MIVS was effective in improving visual function and anatomy in patients with radiation-related retinal detachment. Tumors decreased in size and there was no evidence of recurrence or tumor dissemination. This combined procedure addresses the modifiable causes of visual loss in patients with previously treated malignant uveal melanoma and has the potential to enhance their visual function.
- 1 November 2012
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 43 (6)
Pseudohypopyon as a Clinical Manifestation in Metastatic Lung Carcinoma
- 1 November 2012
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 43 (6)
Pseudohypopyon as a Clinical Manifestation in Metastatic Lung Carcinoma
- 1 November 2012
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 43 (6) , e80-4
Intraoperative Spectral-Domain Optical Coherence Tomography in Coats’ Disease
The authors describe the spectral-domain optical coherence tomography findings in three patients undergoing examinations under anesthesia for treatment of Coats’ disease. Patients were treated using a multifaceted approach of intravitreal bevacizumab and indirect diode laser vascular ablation. A handheld, portable spectral-domain optical coherence tomography system was used as a novel and critical intraoperative tool in differentiating Coats’ disease from diffuse retinoblastoma and other simulating conditions and to monitor reductions in subretinal and intraretinal exudation during the course of treatment.
- 1 November 2012
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 43 (6) , e80-4
Intraoperative Spectral-Domain Optical Coherence Tomography in Coats’ Disease
The authors describe the spectral-domain optical coherence tomography findings in three patients undergoing examinations under anesthesia for treatment of Coats’ disease. Patients were treated using a multifaceted approach of intravitreal bevacizumab and indirect diode laser vascular ablation. A handheld, portable spectral-domain optical coherence tomography system was used as a novel and critical intraoperative tool in differentiating Coats’ disease from diffuse retinoblastoma and other simulating conditions and to monitor reductions in subretinal and intraretinal exudation during the course of treatment.
- Open Access
- 1 August 2012
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 6, 1347-53
Intraoperative intravitreal triamcinolone decreases macular edema after vitrectomy with phacoemulsification
Peer reviewed article authored by (Parke III DW, Sisk RA, Murray TG). Read article or submit your manuscript for publishing.
- 1 August 2012
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 6, 1347-53
Open AccessIntraoperative intravitreal triamcinolone decreases macular edema after vitrectomy with phacoemulsification
Peer reviewed article authored by (Parke III DW, Sisk RA, Murray TG). Read article or submit your manuscript for publishing.
- Open Access
- 1 June 2012
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 6, 925-31
Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification
Peer reviewed article authored by (Parke III DW, Sisk RA, Houston SK, Murray TG). Read article or submit your manuscript for publishing.
- 1 June 2012
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 6, 925-31
Open AccessOcular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification
Peer reviewed article authored by (Parke III DW, Sisk RA, Houston SK, Murray TG). Read article or submit your manuscript for publishing.
- Open Access
- 1 May 2012
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 6, 817-830
Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LHBETATAG retinal tumors
Purpose: The purpose of this study was to evaluate the effect of 2-deoxy-D-glucose (2-DG) on the spatial distribution of the genetic expression of key elements involved in angiogenesis, hypoxia, cellular metabolism, and apoptosis in LHBETATAG retinal tumors. Methods: The right eye of each LHBETATAG transgenic mouse (n = 24) was treated with either two or six subconjunctival injections of 2-DG (500 mg/kg) or saline control at 16 weeks of age. A gene expression array analysis was performed on five different intratumoral regions (apex, center, base, anterior-lateral, and posterior-lateral) using Affymetrix GeneChip Mouse Gene 1.0 ST arrays. To test for treatment effects of each probe within each region, a two-way analysis of variance was used. Results: Significant differences between treatment groups (ie, 0, 2, and 6 injections) were found as well as differences among the five retinal tumor regions evaluated (P < 0.01). More than 100 genes were observed to be dysregulated by ≥2-fold difference in expression between the three treatment groups, and their dysregulation varied across the five regions assayed. Several genes involved in pathways important for tumor cell growth (ie, angiogenesis, hypoxia, cellular metabolism, and apoptosis) were identified. Conclusions: 2-DG was found to significantly alter the gene expression in LHBETATAG retinal tumor cells according to their location within the tumor as well as the treatment schedule. 2-DG's effects on genetic expression found here correlate with previous reported results on varied processes involved in its in vitro and in vivo activity in inhibiting tumor cell growth.
- 1 May 2012
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 6, 817-830
Open AccessRetinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LHBETATAG retinal tumors
Purpose: The purpose of this study was to evaluate the effect of 2-deoxy-D-glucose (2-DG) on the spatial distribution of the genetic expression of key elements involved in angiogenesis, hypoxia, cellular metabolism, and apoptosis in LHBETATAG retinal tumors. Methods: The right eye of each LHBETATAG transgenic mouse (n = 24) was treated with either two or six subconjunctival injections of 2-DG (500 mg/kg) or saline control at 16 weeks of age. A gene expression array analysis was performed on five different intratumoral regions (apex, center, base, anterior-lateral, and posterior-lateral) using Affymetrix GeneChip Mouse Gene 1.0 ST arrays. To test for treatment effects of each probe within each region, a two-way analysis of variance was used. Results: Significant differences between treatment groups (ie, 0, 2, and 6 injections) were found as well as differences among the five retinal tumor regions evaluated (P < 0.01). More than 100 genes were observed to be dysregulated by ≥2-fold difference in expression between the three treatment groups, and their dysregulation varied across the five regions assayed. Several genes involved in pathways important for tumor cell growth (ie, angiogenesis, hypoxia, cellular metabolism, and apoptosis) were identified. Conclusions: 2-DG was found to significantly alter the gene expression in LHBETATAG retinal tumor cells according to their location within the tumor as well as the treatment schedule. 2-DG's effects on genetic expression found here correlate with previous reported results on varied processes involved in its in vitro and in vivo activity in inhibiting tumor cell growth.
- Open Access
- 1 March 2012
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 6, 447-52
Evaluation of the surgical learning curve for I-125 episcleral plaque placement for the treatment of posterior uveal melanoma: a two decade review
Peer reviewed article authored by (Shah NV, Houston SK, Murray TG, Markoe AM). Read article or submit your manuscript for publishing.
- 1 March 2012
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 6, 447-52
Open AccessEvaluation of the surgical learning curve for I-125 episcleral plaque placement for the treatment of posterior uveal melanoma: a two decade review
Peer reviewed article authored by (Shah NV, Houston SK, Murray TG, Markoe AM). Read article or submit your manuscript for publishing.
- 3 February 2012
- Published by Springer Nature in Lasers in Medical Science
- Vol. 28 (3) , 1025-1034
Lasers for the treatment of intraocular tumors
Lasers are used extensively in ophthalmology for a variety of conditions, including many choroidal and retinal tumors. With technologic advances, current therapy attempts not only to maximize survival with globe-salvaging treatment, but also to preserve vision. Each neoplasm has different indications for primary and adjuvant therapy, as well as differing laser treatment protocols. Additionally, there are numerous laser applications available for use, including laser photocoagulation, transpupillary thermotherapy (TTT), and photodynamic therapy (PDT). The current review outlines the basic principles of laser treatment for intraocular tumors, focusing on the indications, treatment protocols, efficacy, and safety, while also presenting the latest advances in intraocular tumor treatment.
- 3 February 2012
- Published by Springer Nature in Lasers in Medical Science
- Vol. 28 (3) , 1025-1034
Lasers for the treatment of intraocular tumors
Lasers are used extensively in ophthalmology for a variety of conditions, including many choroidal and retinal tumors. With technologic advances, current therapy attempts not only to maximize survival with globe-salvaging treatment, but also to preserve vision. Each neoplasm has different indications for primary and adjuvant therapy, as well as differing laser treatment protocols. Additionally, there are numerous laser applications available for use, including laser photocoagulation, transpupillary thermotherapy (TTT), and photodynamic therapy (PDT). The current review outlines the basic principles of laser treatment for intraocular tumors, focusing on the indications, treatment protocols, efficacy, and safety, while also presenting the latest advances in intraocular tumor treatment.